Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Churg-Strauss Disease Workup

  • Author: Robert Stanley Rust, Jr, MD, MA; Chief Editor: Amy Kao, MD  more...
 
Updated: Oct 13, 2014
 

Laboratory Studies

See the list below:

  • The first (prodromal) phase of Churg-Strauss disease (CSD) consists of asthma usually in association with other typical allergic features, which may include eosinophilia. During the second phase, the clinical presentation with CSD, eosinophilia is characteristic (see below) and ANCAs with perinuclear staining pattern (pANCAs) are detected.
  • Where possible, the diagnosis is confirmed by demonstration of angiographic abnormalities in affected organs and by pathognomonic biopsy findings (see Histologic Findings).
  • According to the American College of Rheumatology criteria, clinical diagnosis is established when 4 of the following manifestations are documented: (1) allergic history, (2) asthma, (3) eosinophilia, (4) migratory pulmonary infiltrates, (5) paranasal sinus abnormality, (6) mononeuropathy or polyneuropathy, and (7) demonstration of extravascular eosinophilic infiltration of tissues on biopsy.
  • Eosinophil count
    • Once the second phase of Churg-Strauss disease is reached, eosinophilia (>1500/µL or >10% of total peripheral WBCs) is found on the peripheral blood film of at least 90% of untreated patients.
    • Mean values for absolute eosinophil counts are in the range of 5,000-9,000/µL, but, in rare instances, counts may exceed 100,000/µL. Thus, the history of asthma with the ensuing development of eosinophilia is highly suggestive of Churg-Strauss disease.
    • Treatment of asthmatic manifestations of the first stage of Churg-Strauss disease with corticosteroids may promptly resolve this characteristic finding. The prompt resolution of eosinophilia with corticosteroid treatment is itself characteristic of Churg-Strauss disease.
    • Intermittent elevations of eosinophil counts during the third phase of Churg-Strauss disease may presage a relapse of systemic vasculitis.
  • Elevations of ANCA titers are found in 50-65% of cases of Churg-Strauss disease; these are predominantly pANCAs directed against myeloperoxidase epitopes.[27]
  • Enzyme-linked immunosorbent assays specific for antimyeloperoxidase antibodies were positive in 10 of 11 patients in whom this test was performed by Guillevin et al.[27]
  • Serum IgE concentrations are elevated in three quarters of patients in the second or third phase of Churg-Strauss disease.
  • Erythrocyte sedimentation rate (ESR) and other indices suggestive of the presence of acute-phase reactants may be elevated. Abnormality of sedimentation rate may rapidly (and characteristically, as is also true of eosinophilia) disappear within a few days of treatment with corticosteroids.
  • Testing for rheumatoid factor is positive in approximately 70% of cases.
  • False-positive precipitin test results for syphilis have been reported.
  • Lactate dehydrogenase (LDH) level may be elevated and, as with eosinophilia and elevated sedimentation rate, may correct within a day or a few days after initiation of corticosteroid treatment.
  • Blood urea nitrogen and creatinine levels may be elevated in individuals who develop ANCA-associated renal vasculitis. Gross or microscopic hematuria and pyuria may be found and are due to inflammatory glomerulonephritis, although they may be misinterpreted as representing urinary tract infection. Dysmorphic red cells or red-cell casts in the urine sediment are consistent with the presence of glomerulonephritis; high-grade proteinemia is also suggestive, although the absence of proteinuria does not exclude glomerulonephritis.
Next

Imaging Studies

See the list below:

  • Chest radiographs
    • Chest radiographs demonstrate pulmonary infiltrates in at least half of the patients in the second phase of Churg-Strauss disease and a greater percentage in the third phase of the disease. Typically, these are transient patchy alveolar infiltrates, usually without preferential, lobar, or segmental distribution. In some instances, a diffuse interstitial infiltrative pattern may be apparent.
    • Lungs may be hyperinflated.
    • Nonsegmental reticulonodular opacities without cavitation may be found. These may be solitary but may be multiple in more advanced cases. In some patients with advanced disease, striking bilateral reticulonodular opacities are observed.
    • Bronchial walls may be thickened.
    • Enlarged intrapulmonary lymph nodes may be found in some cases. This unusual finding suggests Churg-Strauss disease in asthmatic patients who have no history of heavy smoking.
    • Pleural effusions are not common. Pulmonary hemorrhage is a particularly suggestive and ominous sign in Churg-Strauss disease.
    • Imaging of the heart may reveal cardiomegaly or pericardial effusion.
  • CT scan of the lungs
    • CT scan of the lungs demonstrates the above-mentioned findings of Churg-Strauss disease even more clearly. In most cases of advanced disease, thin-section lung CT scan also reveals the highly suggestive finding of bilateral, ground-glass pulmonary opacity.
    • Subpleural airspace consolidation is an additional feature in about half of cases, whereas more widespread consolidation is discerned occasionally.
    • Occasional finding of centrolobular nodular densities within the background ground-glass opacity is highly suggestive of Churg-Strauss disease. This change is much more apparent on CT scan than on plain radiographs, as is the thickening of interlobular septi and bronchial wall.
    • Increased vascular wall caliber also may be discerned.
    • Enlarged hilar or mediastinal lymph nodes also are apparent on pulmonary thin-section CT scan in many patients with Churg-Strauss disease, representing an opportunity for diagnostic biopsy.
    • Pleural or pericardial effusions occasionally are detected.
  • Results of abdominal or renal angiography usually are negative in Churg-Strauss disease. However, Churg-Strauss disease may account for less than 5% of all cases of ANCA-associated renal vasculitis, whereas microscopic polyangiitis (MPA) accounts for approximately half, and Wegener granulomatosis (WG) approximately one third of such cases.
  • MRI of the brain in patients with CNS manifestations may reveal vascular territory infarction, with or without hemorrhage. Areas of bright signal on T2-weighted MRI suggestive of vasculitis may be found.[34]
Previous
Next

Other Tests

See the list below:

  • Electrophysiological studies
    • Electrophysiological studies of peripheral nerves may reveal deficits referable to both myelinated and unmyelinated sensory and motor fibers, especially those subserving the lower extremities.
    • Abnormalities in the findings of electrophysiological studies of the sciatic nerve (including tibial and peroneal branches) typically are more profound than those in the radial, median, and cubital nerves. The absence of conduction blocks may be helpful in distinguishing Churg-Strauss mononeuritis multiplex from chronic inflammatory demyelinating polyneuropathy.
    • Patients may be found to manifest acute-onset reduction or absence of sensory nerve action potentials.
Previous
Next

Procedures

See the list below:

  • Procedures that may be valuable in the diagnosis of Churg-Strauss disease have been reviewed and include the following:
    • Biopsy specimens of skin, hilar lymph nodes, lung parenchyma, or peripheral nerve demonstrate the characteristic vasculitis. Kidney biopsy sample may show segmental necrotizing glomerulonephritis with crescent formation, possibly including highly characteristic eosinophilic infiltration of the renal interstitium.
    • Electrophysiological studies of peripheral nerves
Previous
Next

Histologic Findings

See the list below:

  • Biopsy results may demonstrate eosinophilic vasculitis, especially involving the outer zone of the adventitia of medium (10-150 μ m) to small (30-50 μ m) arteries. However, it may be found that infiltrating cells are predominantly lymphocytic while eosinophils may be less prominent or even rare. Vascular wall necrosis with loss of inner elastic vascular lamina and associated hyaline degeneration may be observed. Involved vessels often show occlusion and recanalization. Granuloma formation is rare. The region of arteriopathic change chiefly consists of a central eosinophilic core surrounded by an inflammatory exudate consisting of macrophages, epithelioid cells, and giant cells. Similarly constituted inflammatory exudate may infiltrate the perivascular surround. Fibrinoid necrosis of the vascular media may be discerned.
  • Nerve biopsy specimens may show similar vascular changes in the epineural space in as many as half of all cases with Churg-Strauss neuropathy. Focal loss of myelinated nerves and subperineural edema is characteristic. Immunohistochemical changes on biopsy specimens may confirm the presence of CD4-, CD45 RO- or CD8+ T cells, CD3+ Pan-T lymphocytes, or CD-68 positive macrophages. MHC-class I cells (beta2-microglobulin positive) and MHC class II cells (HLA-DR) may be found—the later particularly in the endoneurium, accompanied by CD68+ macrophages. CD20+ B cells are comparatively rare as are deposits of IgG or C3d complement.
  • Histopathologic studies of a biopsy specimen of affected skin areas reveal small-vessel arteriopathy with granuloma formation in the vascular walls. Enlarged intrapulmonary, hilar, or mediastinal lymph nodes or pulmonary nodules, if biopsied, may reveal similar characteristic histologic abnormalities.
  • Biopsy of lung parenchyma may show tissue injury and eosinophilia without necrotizing vasculitis or the presence of extravascular granulomata.
  • Nerve biopsies reveal vasculitic epineural necrosis in more than half of patients with clinical neuropathy. As has been noted, the predominant cell type within the epineural inflammatory exudate is lymphocytes expressing CD8+ or CD4+ T-cell markers. Lesser numbers of eosinophils are found, with small numbers of CD20+ B cells. Scarce deposits of IgG, IgE, and C3d antibodies may be detected.
  • Kidney biopsy may reveal eosinophilic interstitial pauci-immune segmental glomerulonephritis. Occasionally, glomerulonephritis with IgA deposition is found.
Previous
 
 
Contributor Information and Disclosures
Author

Robert Stanley Rust, Jr, MD, MA Thomas E Worrell Jr Professor of Epileptology and Neurology, Co-Director of FE Dreifuss Child Neurology and Epilepsy Clinics, Director, Child Neurology, University of Virginia School of Medicine; Chair-Elect, Child Neurology Section, American Academy of Neurology

Robert Stanley Rust, Jr, MD, MA is a member of the following medical societies: Child Neurology Society, Society for Pediatric Research, American Headache Society, International Child Neurology Association, American Academy of Neurology, American Epilepsy Society, American Neurological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kenneth J Mack, MD, PhD Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic

Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, Society for Neuroscience

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Have stock from Cellectar Biosciences; have stock from Varian medical systems; have stock from Express Scripts.

Additional Contributors

Robert J Baumann, MD Professor of Neurology and Pediatrics, Department of Neurology, University of Kentucky College of Medicine

Robert J Baumann, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, Child Neurology Society

Disclosure: Nothing to disclose.

References
  1. Davies DJ, Moran JE. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. BMJ. 1982. 285:606.

  2. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951 Mar-Apr. 27(2):277-301. [Medline].

  3. Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. 1977 Aug. 52(8):477-84. [Medline].

  4. Lanham JG. Churg-Strauss syndrome. Br J Hosp Med. 1992 May 6-19. 47(9):667-73. [Medline].

  5. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990 Aug. 33(8):1094-100. [Medline].

  6. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb. 37(2):187-92. [Medline].

  7. Lie JT. Nomenclature and classification of vasculitis: plus ça change, plus c'est la même chose. Arthritis Rheum. 1994 Feb. 37(2):181-6. [Medline].

  8. Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int. 1994 Jul. 46(1):1-15. [Medline].

  9. Cohen P, Guillevin L, Baril L, Lhote F, Noel LH, Lesavre P. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol. 1995 Mar-Apr. 13(2):193-8. [Medline].

  10. Tervaert JW, Goldschmeding R, Elema JD, von dem Borne AE, Kallenberg CG. Antimyeloperoxidase antibodies in the Churg-Strauss syndrome. Thorax. 1991 Jan. 46(1):70-1. [Medline].

  11. Tervaert JW, Goldschmeding R, Elema JD, et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum. 1990 Aug. 33(8):1264-72. [Medline].

  12. Watts RA, Scott DG. Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol. 1997 May. 11(2):191-217. [Medline].

  13. Capizzi SA, Specks U. Does infection play a role in the pathogenesis of pulmonary vasculitis?. Semin Respir Infect. 2003 Mar. 18(1):17-22. [Medline].

  14. Ramentol-Sintas M, Martínez-Valle F, Solans-Laqué R. Churg-Strauss Syndrome: An evolving paradigm. Autoimmun Rev. 2012 Dec. 12(2):235-40. [Medline].

  15. Wiik A. Autoantibodies in vasculitis. Arthritis Res Ther. 2003. 5(3):147-52. [Medline].

  16. Arm JP, Lee TH. Sulphidopeptide leukotrienes in asthma. Clin Sci (Lond). 1993 May. 84(5):501-10. [Medline].

  17. Drazen JM, Israel E. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med. 1998 Dec. 158(6):1697-8. [Medline].

  18. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999 Jan 21. 340(3):197-206. [Medline].

  19. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998 Feb 11. 279(6):455-7. [Medline].

  20. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest. 1995 Aug. 108(2):320-3. [Medline].

  21. D'Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome?. BMJ. 1999 Feb 20. 318(7182):475-6. [Medline].

  22. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf. 2003. 26(7):483-518. [Medline].

  23. Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med. 2003. 2(2):139-56. [Medline].

  24. Finkel TH, Hunter DJ, Paisley JE, Finkel RS, Larsen GL. Drug-induced lupus in a child after treatment with zafirlukast (Accolate). J Allergy Clin Immunol. 1999 Mar. 103(3 Pt 1):533-4. [Medline].

  25. Haim DY, Lippmann ML, Goldberg SK, Walkenstein MD. The pulmonary complications of crack cocaine. A comprehensive review. Chest. 1995 Jan. 107(1):233-40. [Medline].

  26. Orriols R, Munoz X, Ferrer J, Huget P, Morell F. Cocaine-induced Churg-Strauss vasculitis. Eur Respir J. 1996 Jan. 9(1):175-7. [Medline].

  27. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999 Jan. 78(1):26-37. [Medline].

  28. Shanks M, Ignaszewski AP, Chan SY, Allard MF. Churg-Strauss syndrome with myocarditis manifesting as acute myocardial infarction with cardiogenic shock: case report and review of the literature. Can J Cardiol. 2003 Sep. 19(10):1184-8. [Medline].

  29. Lin YC, Oliveira GH, Villa-Forte A. Churg-Strauss syndrome and persistent heart failure: active disease or damage?. J Clin Rheumatol. 2013 Oct. 19(7):390-2; discussion 419. [Medline].

  30. Tatsukawa H, Nagano S, Umeno Y, Oribe M. Churg-strauss syndrome with cholecystitis and renal involvement. Intern Med. 2003 Sep. 42(9):893-6. [Medline].

  31. Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005 Aug. 7(4):270-5. [Medline].

  32. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr. 41(4):776-84. [Medline].

  33. Kawakami T, Soma Y, Kawasaki K, Kawase A, Mizoguchi M. Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome. Arch Dermatol. 2005 Jul. 141(7):873-8. [Medline].

  34. Eyler AE, Ahmad FA, Jahangir E. Magnetic resonance imaging of the cardiac manifestations of Churg-Strauss. JRSM Open. 2014 Apr. 5(4):2054270414525370. [Medline]. [Full Text].

  35. Abril A, Calamia KT, Cohen MD. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum. 2003 Oct. 33(2):106-14. [Medline].

  36. Azzopardi C, Montefort S, Mallia C. Cardiac involvement and left ventricular failure in a patient with the Churg-Strauss syndrome. Adv Exp Med Biol. 1999. 455:547-9. [Medline].

  37. Barry C, Davis S, Garrard P, Ferguson IT. Churg-Strauss disease: deterioration in a twin pregnancy. Successful outcome following treatment with corticosteroids and cyclophosphamide. Br J Obstet Gynaecol. 1997 Jun. 104(6):746-7. [Medline].

  38. Berger JR, Wei T, Wilson D. Idiopathic granulomatous angiitis of the CNS manifesting as diffuse white matter disease. Neurology. 1998 Dec. 51(6):1774-5. [Medline].

  39. Bili A, Condemi JJ, Bottone SM, Ryan CK. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists. J Allergy Clin Immunol. 1999 Nov. 104(5):1060-5. [Medline].

  40. Boggi U, Mosca M, Giulianotti PC, Naccarato AG, Bombardieri S, Mosca F. Surviving catastrophic gastrointestinal involvement due to Churg-Strauss syndrome: report of a case. Hepatogastroenterology. 1997 Jul-Aug. 44(16):1169-71. [Medline].

  41. Brooklyn TN, Prouse P, Portmann B, Ramage JK. Churg-Strauss syndrome and granulomatous cholangiopathy. Eur J Gastroenterol Hepatol. 2000 Jul. 12(7):809-11. [Medline].

  42. Bruce IN, Bell AL. A comparison of two nomenclature systems for primary systemic vasculitis. Br J Rheumatol. 1997 Apr. 36(4):453-8. [Medline].

  43. Burke AP, Sobin LH, Virmani R. Localized vasculitis of the gastrointestinal tract. Am J Surg Pathol. 1995 Mar. 19(3):338-49. [Medline].

  44. Caballero J, Zayas R, Arana R, Cano L, Berruezo A, Pinero C. [Churg-Strauss syndrome with pericardial and myocardial involvement]. Rev Esp Cardiol. 1999 Sep. 52(9):745-7. [Medline].

  45. Chen KR, Su WP, Pittelkow MR, Leiferman KM. Eosinophilic vasculitis syndrome: recurrent cutaneous eosinophilic necrotizing vasculitis. Semin Dermatol. 1995 Jun. 14(2):106-10. [Medline].

  46. Cho KH, Kim YG, Yang SG, Lee DY, Chung JH. Inflammatory nodules of the lower legs: a clinical and histological analysis of 134 cases in Korea. J Dermatol. 1997 Aug. 24(8):522-9. [Medline].

  47. Davis MD, Daoud MS, McEvoy MT, Su WP. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol. 1997 Aug. 37(2 Pt 1):199-203. [Medline].

  48. Dietz A, Hubner C, Andrassy K. [Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome)]. Laryngorhinootologie. 1998 Feb. 77(2):111-4. [Medline].

  49. Dillon MJ. Childhood vasculitis. Lupus. 1998. 7(4):259-65. [Medline].

  50. Dinç A, Soy M, Pay S, Simsek I, Erdem H, Sobaci G. A case of Churg-Strauss syndrome presenting with cortical blindness. Clin Rheumatol. 2000. 19(4):318-20. [Medline].

  51. Eustace JA, Nadasdy T, Choi M. Disease of the month. The Churg Strauss Syndrome. J Am Soc Nephrol. 1999 Sep. 10(9):2048-55. [Medline].

  52. Falk RJ, Nachman PH, Hogan SL, Jennette JC. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol. 2000 May. 20(3):233-43. [Medline].

  53. Ferro JM. Vasculitis of the central nervous system. J Neurol. 1998 Dec. 245(12):766-76. [Medline].

  54. Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol. 1995 Jan. 7(1):11-9. [Medline].

  55. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum. 1992 Feb. 35(2):208-15. [Medline].

  56. Hagen EC, Andrassy K, Csernok E, et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods. 1996 Sep 13. 196(1):1-15. [Medline].

  57. Hauschild S, Csernok E, Schmitt WH, Gross WL. Antineutrophil cytoplasmic antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients. J Rheumatol. 1994 Jun. 21(6):1173-4. [Medline].

  58. Hellemans S, Dens J, Knockaert D. Coronary involvement in the Churg-Strauss syndrome. Heart. 1997 Jun. 77(6):576-8. [Medline]. [Full Text].

  59. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005 Jun. 1051:121-31. [Medline].

  60. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 2003 Nov-Dec. 21(6 Suppl 32):S69-77. [Medline].

  61. Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother. 2004 Jan. 5(1):25-35. [Medline].

  62. Hoffman PM, Godfrey T, Stawell RJ. A case of Churg-Strauss syndrome with visual loss following central retinal artery occlusion. Lupus. 2005. 14(2):174-5. [Medline].

  63. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989 Nov. 135(5):921-30. [Medline].

  64. Kim Y, Lee KS, Choi DC, Primack SL, Im JG. The spectrum of eosinophilic lung disease: radiologic findings. J Comput Assist Tomogr. 1997 Nov-Dec. 21(6):920-30. [Medline].

  65. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003 Dec. 42(6):1149-53. [Medline].

  66. Lamprecht P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin Exp Immunol. 2005 Aug. 141(2):201-10. [Medline].

  67. Lamprecht P. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev. 2005 Jan. 4(1):28-34. [Medline].

  68. Langford CA, Sneller MC. New developments in the treatment of Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Curr Opin Rheumatol. 1997 Jan. 9(1):26-30. [Medline].

  69. Lhote F, Cohen P, Genereau T, Gayraud M, Guillevin L. Microscopic polyangiitis: clinical aspects and treatment. Ann Med Interne (Paris). 1996. 147(3):165-77. [Medline].

  70. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am. 1995 Nov. 21(4):883-909. [Medline].

  71. Marmursztejn J, Guillevin L, Trebossen R, Cohen P, Guilpain P, Pagnoux C, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford). 2012 Aug 29. [Medline].

  72. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997 Aug. 56(8):481-7. [Medline].

  73. Matsuo K, Tomioka T, Tajima Y, et al. Allergic granulomatous angitis (Churg-Strauss syndrome) with multiple intestinal fistulas. Am J Gastroenterol. 1997 Oct. 92(10):1937-8. [Medline].

  74. Metzler C, Lamprecht P, Hellmich B, Reuter M, Arlt AC, Gross WL. Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon {alpha}. Ann Rheum Dis. 2005 Aug. 64(8):1242-3. [Medline].

  75. Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2012 Aug 11. [Medline].

  76. Muschen M, Warskulat U, Perniok A, et al. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol. 1999 Sep. 155(3):915-25. [Medline].

  77. Niles JL. Antineutrophil cytoplasmic antibodies in the classification of vasculitis. Annu Rev Med. 1996. 47:303-13. [Medline].

  78. Pellissier JF, Figarella-Branger D, Serratrice G. [Neuromuscular diseases with eosinophilia]. Med Trop (Mars). 1998. 58(4 Suppl):471-6. [Medline].

  79. Primack SL, Müller NL. Radiologic manifestations of the systemic autoimmune diseases. Clin Chest Med. 1998 Dec. 19(4):573-86, vii. [Medline].

  80. Reid AJC, Harrison RA, Watkin SW, McCann BG, and Scott DGI. Churg-Strauss syndrome in a district hospital. Q J Med. 1998. 91:219-229.

  81. Rutgers A, Heeringa P, Tervaert JW. The role of myeloperoxidase in the pathogenesis of systemic vasculitis. Clin Exp Rheumatol. 2003 Nov-Dec. 21(6 Suppl 32):S55-63.

  82. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005 Nov 1. 143(9):632-8. [Medline].

  83. Sakamoto S, Ohba S, Eguchi K, et al. Churg-Strauss syndrome presenting with subarachnoid hemorrhage from ruptured dissecting aneurysm of the intracranial vertebral artery. Clin Neurol Neurosurg. 2005 Aug. 107(5):428-31. [Medline].

  84. Sanders JS, Stegeman CA, Kallenberg CG. The Th1 and Th2 paradigm in ANCA-associated vasculitis. Kidney Blood Press Res. 2003. 26(4):215-20. [Medline].

  85. Sharma BK, Daga MK, Sharma M. A limited form of Churg-Strauss syndrome presenting without asthma and eosinophilia. Med J Aust. 2004 Nov 1. 181(9):498-9. [Medline].

  86. Somogyi A, Muzes G, Molnar J, Tulassay Z. Drug-related Churg-Strauss syndrome?. Adverse Drug React Toxicol Rev. 1998 Jun-Sep. 17(2-3):63-74. [Medline].

  87. Sonneville R, Lagrange M, Guidoux C, et al. [The association of cardiac involvement and ischemic stroke in Churg Strauss syndrome]. Rev Neurol (Paris). 2006 Feb. 162(2):229-32. [Medline].

  88. Steinfeld S, Golstein M, De Vuyst P. Chronic eosinophilic pneumonia (CEP) as a presenting feature of Churg-Strauss syndrome (CSS). Eur Respir J. 1994 Nov. 7(11):2098. [Medline].

  89. Sudo K, Tashiro K. Idiopathic granulomatous angiitis of the CNS manifesting as diffuse white matter disease. Neurology. 1998 Dec. 51(6):1774; author reply 1775. [Medline].

  90. Sullivan EJ, Hoffman GS. Pulmonary vasculitis. Clin Chest Med. 1998 Dec. 19(4):759-76, ix. [Medline].

  91. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998 Sep 1. 129(5):370-4. [Medline].

  92. Terasaki F, Hayashi T, Hirota Y, et al. Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome. Heart Vessels. 1997. 12(1):43-8. [Medline].

  93. Thuy GN, Cuguilliere A, Arteaga C, Miltgen J, Bonnet D. [Idiopathic chronic eosinophilic pneumonia]. Med Trop (Mars). 1998. 58(4 Suppl):455-8. [Medline].

  94. Vital C, Vital A, Canron MH, et al. Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst. 2006 Mar. 11(1):20-9. [Medline].

  95. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000 Feb. 43(2):414-9. [Medline].

  96. Weissler JC. Syndromes of severe asthma. Am J Med Sci. 2000 Mar. 319(3):166-76. [Medline].

  97. Wolf M, Rose H, Smith RN. Case records of the Massachusetts General Hospital. Case 28-2005. A 42-year-old man with weight loss, weakness, and a rash. N Engl J Med. 2005 Sep 15. 353(11):1148-57. [Medline].

  98. Yoshihara K, Arimura Y, Kobayashi O, et al. [Clinical study on five myeloperoxidase specific anti-neutrophil cytoplasmic antibody (MPO-ANCA) positive Churg-Strauss syndrome cases]. Ryumachi. 1998 Oct. 38(5):696-704. [Medline].

  99. Zhao MH, Short AK, Lockwood CM. Antineutrophil cytoplasm autoantibodies and vasculitis. Curr Opin Hematol. 1995 Jan. 2(1):96-102. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.